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health care system unless an efficient and safe outpa-
tient program is developed.
Fortunately, prolonged hospital discharge for patients
with an LVAD has become possible for several reasons:
First, confidence in the devices has allowed patients,
their families, and health care providers to be more
comfortable with outpatient therapy. Second, the
devices have become durable enough to allow extended
durations of support. Third, the perception of the LVAD
has changed from a last-resort therapeutic option to that
of a rehabilitation-enhancing, patient-empowering
device.1 As LVAD technology has matured, programs
are now being asked to evaluate patients’ outcomes such
as satisfaction, functional capabilities, and quality-of-
life issues, as well as to assess the raw survival statistics
of their programs.2-7
The literature on LVAD outpatients is sparse, with the
largest reported experience of LVAD patients dis-
charged home consisting of 21 patients accumulated
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SIX-YEAR EXPERIENCE OF CARING FOR FORTY-FOUR PATIENTS WITH A LEFT VENTRICULAR
ASSIST DEVICE AT HOME: SAFE, ECONOMICAL, NECESSARY
T he economic value of a 103-day hospitalization, ouraverage bridge to transplantation time, for a patient
with a left ventricular assist device (LVAD) who is self-
sufficient and wants to leave the hospital is unclear.
With increasing numbers of implantations, LVAD pro-
grams can put a financial strain on a hospital and a
from the 4 most experienced LVAD programs.8 The
LVAD is not widely recognized in the medical commu-
nity as a device reliable enough to support a patient at
home. We reviewed our 6-year experience with LVAD
outpatients to assess the safety and the cost-effective-
ness of such a program.
Methods
The medical records of all patients receiving a TCI
(Thermo Cardiosystems, Inc, Woburn, Mass) vented-electric
(VE) LVAD between February 1993 and January 1999 were
reviewed. Forty-four patients were eligible for the study
because they were discharged home with a TCI VE LVAD in
place. Our discharge criteria have been described in previous
articles (Table I).1,9,10 Discharging a patient to a rehabilitation
center, to medically supervised housing, on a day trip, or home
overnight did not qualify patients for this study. Inclusion of
only patients discharged home without restriction allowed us
to assess the safety and economics of outpatient LVAD care as
though a permanent device had been implanted.
LVAD support outcomes were categorized as transplanta-
tion, explantation, or death. Outpatient morbidity was consid-
ered to be those complications that arose while the patient
was discharged from the hospital. Complications that arose in
the hospital but were carried over into outpatient support
were not considered. A bleeding event was defined as the
need to transfuse, admit, or operate on a patient because of
hemorrhage associated with the LVAD. Device-related infec-
tions were defined as a positive culture from the LVAD that
necessitated medical or surgical intervention. LVAD endo-
carditis was defined as an infection of the pseudointimal layer
of an LVAD resulting in positive LVAD lining and blood cul-
tures necessitating 6 weeks of intravenous antibiotics. A
non–device-related infection was a positive culture from any
non-device source accompanied by a white cell count over
12,000/mm3 or a temperature greater than 100.5°F that clini-
cally required antibiotics. Right-sided heart failure was
defined as the need for inhaled nitric oxide or a right ventric-
ular assist device. Any stroke, transient ischemic attack, neu-
ropathy, or encephalopathy was considered a neurologic
event. No systemic anticoagulation in the form of heparin or
warfarin sodium (Coumadin) was given to the LVAD outpa-
tients. Antiplatelet therapy in the form of aspirin was given to
several outpatients. Any end-organ dysfunction caused by an
embolus was considered a thromboembolic event. A major
malfunction was defined as a pump malfunction, resulting in
hemodynamic compromise and/or necessitating LVAD
replacement. A minor malfunction was defined as an occur-
rence necessitating only a repair or replacement of the extra-
corporeal device, such as the controller or the battery system.
Some of these complications resulted in unscheduled hospi-
talizations. Hospitalizations for scheduled admissions that
were not a result of outpatient therapy, but for evaluations that
either an outpatient or inpatient would have required, were
not counted as readmissions.
Costs of all supplies were priced according to a Drug
Topics Redbook written by Medical Economics Company
(Montvale, NJ, 1998).11 Items not included in this book were
priced by averaging their cost at 3 surgical supply stores in
the New York City area. The professional fees represent the
prices set by the American Medical Association in the 1999
current procedural terminology codes.12 In-hospital costs
were gathered from the financial and billing departments at
Columbia-Presbyterian Medical Center. All data on sexual
activity, working, and driving were collected by personal
interview. Results on the incidence of these three activities
used the number of people engaging in these activities before
LVAD implantation as the denominator.
All results are reported as a mean ± the standard error. The
95% confidence intervals for the incidence per outpatient
were calculated by the Exact Method for Binomial
Proportions. The 95% confidence intervals for the incidence
of event per outpatient month were calculated by the Exact
Method for Poisson Parameters.
Results
Fifty-three (59%) of the 90 patients who received
TCI VE LVADs were released from the hospital. Nine
patients were allowed day trips only and 44 (49%) were
discharged home from the hospital completely. Our
results will focus on these 44 patients (91% male)
whose mean age was 46 ± 2 years. This group spent a
total of 4546 days (12.5 years) at home with an average
of 103 ± 16 days of outpatient support (median 71
days; range 9-436 days). This cohort spent 62% ± 4%
of their LVAD support time as outpatients. All but 4 of
these 44 patients were sent home before the Food and
Drug Administration (FDA) approval of the TCI VE
LVAD in September of 1998.
The outcomes of the 44 patients with LVADs dis-
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Table I. Criteria for discharging LVAD patients*
1. Patient must be hospitalized for at least 30 days after LVAD 
implantation
2. Patient must currently be in New York Heart Association functional 
class I
3. There is echocardiographic evidence indicating that the patient’s 
native heart has sufficient contractility to open the aortic valve 
and maintain an arterial pressure with the LVAD operating at its 
lowest rate
4. Patient must have passed the required training course in the care 
and operation of the device
5. Patient must be accompanied by a trained companion who has 
passed the required training course in the care and operation of 
the device
6. Patient must have in the immediate vicinity required primary and 
backup equipment at all times
*These criteria were used for all the patients in this study; however, with the
FDA approval of the HeartMate VE LVAD, we have implemented new criteria.
charged home and the remaining 46 patients with
LVADs not discharged home are listed in Table II. No
LVAD outpatients died. All outpatients were successful-
ly bridged to transplantation or planned explantation.
The average wait for a heart in the outpatients receiv-
ing transplants was 148 ± 21 days. The average post-
operative length of stay after transplantation for the
outpatients who had LVADs was 18 ± 2 days. Two
patients had the LVAD explanted, one on LVAD sup-
port day 389 and the other on LVAD support day 101.
The first patient had another LVAD placed for recurrent
heart failure on postexplantation day 178. However,
she underwent successful transplantation 89 days later,
spending 75 of these 89 days (84%) at home. The sec-
ond patient is doing well 120 days after explantation.
Complications. A rapid response mechanism created
in case of an outpatient catastrophic event was rarely
implemented, because the frequency of these events or
any outpatient complications in our experience has
been minimal (Table III). This includes the 9 patients
allowed day trips only, who had no complications
while out of the hospital or as a result of being out of
the hospital.
Bleeding events. Three of our outpatients had bleed-
ing complications, 2 requiring surgery. In 2 patients
holes developed in the outflow grafts on the 46th and
352nd days of LVAD support. Both patients were
brought to the clinic, were noted to have decreased
hematocrit values, and were subsequently taken to the
operating room on a nonemergency basis for outflow
graft replacement or repair. The third patient had a self-
limited episode of bleeding on the 64th day of LVAD
support from the driveline tract after sexual activity.
This patient was admitted for 3 days of observation and
was discharged without intervention.
Neurologic/thromboembolic events. Despite no
systemic anticoagulation, no strokes or transient
ischemic attacks occurred in this cohort of patients.
However, 1 patient did have a microembolization to the
retina, causing a transient scotoma of the left eye 83
days after implantation. This patient was admitted for 3
days of observation during which there was no inter-
vention or anticoagulation since no source of emboli
was found. This deficiency resolved almost completely
and did not inhibit the patient from such activities as
snowboarding.
Device-related infections. Eight patients had a
device-related infection while at home. Three of the 5
patients with driveline infections were admitted to the
hospital because of fevers and increased white cell
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Table II. Outcomes of patients with the TCI VE LVAD 
Status No. of patients Transplant recipients Death Explantation Ongoing
Discharged* LVAD recipients 44 42 (96%) 0 2 (4%) 0
Nondischarged LVAD recipients 46 20 (44%) 19 (41%) 2 (4%) 5 (11%)
Total No. of VE LVADs 90 62 (69%) 19 (21%) 4 (4%) 5 (6%)
*Does not include overnight or day trips.
Table III. Complications of LVAD outpatient care
Incidence Incidence of event Resulting mortality 
Type of complication per outpatient 95% CI per outpatient month 95% CI from complication
Bleeding 0.068 (3/44) 0.014-0.190 0.020 0.004-0.059 0
Operate for bleeding 0.045 (2/44) 0.006-0.160 0.013 0.002-0.048 0
Stroke/TIA 0 0-0.081 0 0-0.025 N/A
Thromboembolic event 0.023 (1/44) 0.001-0.120 0.007 0-0.037 0
Device-related infection 0.180 (8/44) 0.082 -0.330 0.053 0.023-0.110 0
Admit for device infection 0.140 (6/44) 0.052-0.270 0.040 0.015-0.087 0
Operate for device infection 0 0-0.081 0 0-0.025 N/A
Non–device-related infection 0.091 (4/44) 0.025-0.217 0.026 0.007-0.069 0
Right heart failure 0 0-0.081 0 0-0.025 N/A
Major malfunction 0.068 (3/44) 0.014-0.190 0.020 0.004-0.059 0
Minor malfunction 0.460 (20/44) 0.300-0.610 0.440 0.430-0.460 0
Admit for minor malfunction 0.023 (1/44) 0.001-0.120 0.007 0-0.037 0
Unscheduled hospitalization 0.270 (12/44) 0.150-0.430 0.120 0.071-0.190 0
CI, Confidence interval; TIA, transient ischemic attack.
counts while receiving oral antibiotics. After successful
intravenous antibiotic therapy, 2 of these patients
resumed their outpatient LVAD care and 1 patient
underwent transplantation on the 7th day in the hospi-
tal. The other 2 patients with a driveline infection were
treated with oral antibiotics as outpatients with no fur-
ther complications. One patient had a pocket infection
associated with high fevers and drainage from the
abdominal wound. He was admitted and successfully
treated with a 7-day course of intravenous antibiotics.
Two patients with LVAD endocarditis13 were admitted
with bacteremia and fever but the fever abated with
intravenous antibiotic therapy. Both LVADs were
explanted on those admissions, one for functional
improvement of the native heart and the other for a
transplant. Positive pseudointimal lining cultures at
explant and pre-explant blood cultures for Pseudo-
monas aeruginosa and Staphylococcus epidermidis
confirmed our suspicions of LVAD endocarditis.
Non–device-related infections. The immune func-
tion of patients receiving long-term LVAD support has
been theorized to become deficient by the prolonged
and ongoing stimulation of the immune system by the
LVAD, a large antigen. Therefore we evaluated whether
these LVAD outpatients contracted a higher frequency
of other types of infections (ie, pneumonia, urinary
tract) not directly involving the device.14,15 Only 4
non–device-related infections were identified. Two
were central line infections, both necessitating admis-
sion, in patients receiving immunoglobulin G for posi-
tive panel reactive antibody tests. These infections
resolved with line removal and intravenous antibiotics.
The third incident was a Streptococcus throat infection
treated on an outpatient basis and the fourth, a urinary
tract infection, also treated on an outpatient basis.
There was no case of pneumonia or urosepsis.
Malfunctions. A total of 66 minor malfunctions
affected 20 of 44 outpatients (46%). These included
batteries not fully charging, alarms continuously
sounding, and controllers malfunctioning. The vast
majority of these events were managed by the patient or
in the outpatient clinic. Only one of these events neces-
sitated admission to the hospital, and this was to
observe a new controller for 48 hours.
All three of the major malfunctions in our experience
were recognized in the outpatient setting early and
addressed in an efficient manner that avoided any clin-
ical ramifications. There was no mortality from major
malfunctions. The LVADs malfunctioned in three
ways, all resulting in deficient forward flow: (1) The
cam slope had broken loose, thus inhibiting the pusher
plate from fully compressing the blood chamber; (2)
the LVAD’s ball bearings had worn after 270 days of
support, making the resistance too great for the motor
to work efficiently; and (3) a static shock mistakenly
delivered to the LVAD system damaged the power con-
ductor, sending the LVAD into a basal rate at 40
cycles/min. After LVAD replacement, all patients
recovered without complications, were discharged, and
successfully underwent transplantation after a period of
outpatient support. Thus the fear that the LVAD can
stop, causing sudden death at home, was not realized. 
Unscheduled hospitalizations. There were 18
unscheduled hospitalizations affecting 12 of 44 (27%)
outpatients with a median hospital stay of 7 days and a
range of 3 to 25 days for a total of 171 readmission
days. These days were not included in the 4546 outpa-
tient LVAD support days. These readmissions were
caused by the complications discussed earlier. There
were 8 scheduled admissions, lasting 1 to 4 days. All
were for immunoglobulin G therapy for a positive
panel reactive antibody test except for one that was for
a scheduled angioplasty. All of the patients who were
readmitted were discharged. The 18 unscheduled read-
missions resulted in discharge (15), transplantation (2),
or explantation (1). None of the unscheduled hospital-
izations resulted in death. Until transplantation or
explantation, LVAD outpatients spent 96% of their out-
patient support time at home and healthy. 
Outpatient costs. The costs associated with caring
for an outpatient with an LVAD are listed in Table IV,
and the analysis in Table V shows the estimated cost of
outpatient care over 1 week and over our average out-
patient support time of 103 days. In our experience, the
incidence of readmission per outpatient over this aver-
age time of outpatient support is 0.41 and over a week
is 0.028. The mean cost to readmit an LVAD outpatient
in our hospital is $25,653.16 Using the weekly supply
cost, our typical schedule for follow-up visits, and our
readmission cost, we can estimate the expense of bridg-
ing our LVAD patients to transplantation or explanta-
tion once an outpatient as $13,200. If we exclude read-
missions, the cost to take care of a healthy LVAD
outpatient for 1 month, including weekly clinic visits
and laboratory tests, is $750. If the FDA requirement
for weekly visits is eliminated, as it has been since
September of 1998, the anticipated cost per month
assuming one clinic visit a month would be $600. One
day of room and board on our nonacute surgical floor
costs $1604.
Outpatient activities. The prevalence of 4 activities
in particular was noted to provide a sense whether
LVAD outpatients resume their “normal lives.” On dis-
charge, many patients were driving, working, going to
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school, and resuming sexual activity (Table VI).
Patients returned to being lawyers, musicians, high
school students, and graduate students. However, sever-
al adults did not return to work because their insurance
benefits for LVAD care would have been forfeited.
Worldwide experience. Table VII shows the total
worldwide LVAD outpatient experience as of January
1, 1999, not including day trips or overnight passes,
according to the three main manufacturers of
LVADs.*†‡ A total of 261 patients have been sent home
with a TCI LVAD, 205 patients with a Novacor LVAD
(Novacor Division, Baxter Healthcare Corporation,
Oakland, Calif), and 5 patients with a Thoratec LVAD
(Thoratec Laboratories, Pleasanton, Calif). 
Discussion
The reluctance to discharge patients with an LVAD
stems from the innumerable problems that patients and
caregivers can imagine arising at home and their possi-
bly fatal outcomes. This hesitancy to discharge LVAD
patients was seen in the first attempts at outpatient care,
in which patients were discharged from the hospital but
stayed in medically supervised housing.4,17,18 This is
not surprising since the literature on the safety and reli-
ability of outpatient LVAD care is sparse. The largest
single outpatient program experience was reported by
Columbia-Presbyterian Hospital and consisted of only
19 patients.1 Therefore published proof of the safety
and reliability of outpatient LVADs is not overwhelm-
ing, as seen by a review of the literature (Table
VIII).1,8,17-19 However, data for outpatient LVADs do
exist, even though not reported. To this end, the FDA,
after studying all the outpatient data from the manufac-
tures, approved the only two available portable LVADs
in the United States, the TCI VE HeartMate and the
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Table IV. Outpatient LVAD cost
Type of cost Items (No. needed daily) Cost Unit cost
Professional fee Clinic visit (CPT 99211) (nurse practitioner $50.00 $50.00 (weekly)
or physician)
Laboratory fees Venipuncture (CPT 36415) $10.00 $76.00 (weekly)
Coagulation profile $24.00
Hepatic profile $20.00
Chem 7 profile $8.00
ABC $14.00
Dressing supplies 4 × 4 gauze (6) $0.18 $5.17 (daily)
Sterile gloves (1) $1.14
Nonsterile gloves (1) $1.40
Operation site (1) $1.55
Medications Ferrous sequels (2) $0.32 $3.29 (daily)
Antacid (Pepcid AC) 10 mg (1) $0.28
Multivitamin (1) $0.13
Enteric aspirin (1) $0.20
Captopril 25 mg (3) $0.68
CPT, Current procedural terminology; ABC, automated blood count.
Table V. Cost to bridge LVAD outpatient to transplantation
Monthly cost per 
Type of cost Unit cost Frequency Weekly cost Cost per 103 days healthy outpatient
Professional fees $50.00 Weekly $50.00 $735.71 $200.00
Laboratory fees $76.00 Weekly $76.00 $1,118.29 $304.00
Dressing changes $5.17 Daily $36.19 $532.51 $151.10
Medications $3.29 Daily $23.03 $338.87 $98.70
Readmission $25,653 0.0040/day $718.28 $10,462.09 —
Total N/A N/A $903.50 $13,187.47 $753.80
Our average length of outpatient support (103 ± 16 days). Healthy outpatient means no readmissions. N/A, Not available.
*Jacobs D. Novacor out-of-hospital experience. Personal communi-
cation, December 1998.
†Krauskopf T. Summary of patients in release program: vented elec-
tric LVAS. Personal communications, December 1998.
‡Marchesani G. TLC-II portable driver outpatient experience.
Personal communications, December 1998.
Novacor 100 W LVAD, for outpatient use in September
of 1998. A third device, the Thoratec TLC II, which can
serve as a right, left, or biventricular assist device, has
been available for outpatient use in Canada since
November 1998 and in Europe since May 1998 (per-
sonal communication from G. Marchesani, December
1998). The worldwide LVAD outpatient experience of
471 patients with a total of 168 support-years out of the
hospital and a 1.2% per patient-year mortality is
impressive, but unpublished.*†‡ This mortality is a sig-
nificant improvement when compared with the 66% 1-
year mortality of a transplant status I patient with class
IV heart failure or with the 30% 1-year mortality of all
patients on the cardiac transplant list.20,21 There are
also significant improvements in regard to freedom
from hospitalization. Most LVAD recipients are United
Network for Organ Sharing (UNOS) status I, receiving
inotropic support, and waiting in the intensive care unit
with class IV heart failure. Even if these patients
improve and are sent home, an average group of 44
patients with class III or IV heart failure supported for
the same amount of time as our outpatient cohort would
be admitted 50 times (4 times per patient-year),22
whereas our LVAD outpatients were admitted 18 times
(1.4 times per patient-year). Outpatient LVAD care is
not a therapy of the future but a safe therapy for
patients with end-stage heart failure that currently is
being practiced in the United States and around the
world.
Our experience with LVAD outpatients has been pos-
itive and our initial concerns of complications, espe-
cially device failure, occurring with no medical super-
vision were relieved for three main reasons. First,
complications outside the hospital were infrequent,
especially when compared with our in-hospital rate, as
evidenced by our in-hospital non-device and device-
related infection rates of 60% and 27%, respectively,
which are markedly more than our outpatient inci-
dences of 7% and 18%, respectively.13,23 Second, if
they did occur, the outpatient’s LVAD education, the
LVAD personnel access and communication systems,
and the physiologic discharge criteria of adequate left
ventricular function served as safety nets.9,10 These
nets allowed early detection of all complications fol-
lowed by a swift and seamless plan of therapy, avoid-
ing frantic or emergency situations out of the hospital
and resulting in no outpatient mortality. Third, no com-
plications of clinical significance occurred as a result
of being an outpatient; all complications could have
occurred in the hospital. Thus, whether the patients
were in or out of the hospital made no difference in
regard to safety. However, being an outpatient did have
several benefits in terms of cost and quality of life.
Reallocation away from the inpatient setting, the
most costly component of the $35 billion spent on heart
failure treatment every year, to the outpatient setting is
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Table VI. Ability of outpatients to return to “active living”
No. of patients No. of 
involved in activity LVAD outpatients Percent able to 
Activity before LVAD support involved in activity return to activity
Work/school 44 13 30%
Sexually active 30 10 33%
Driving 36 16 44%
Table VII. World experience of LVAD patients discharged home
No. of patients, Outpatient support Mortality 
Device US/non-US in days as outpatient
Novacor 71/134* 32,157 (88.1 y) 0
TCI VE LVAD 141/120 28,981 (79.4 y) 2
Thoratec VAD 0/5 100 (0.3 y) 0
Total 471 61,237 (167.8 y) 2 (0.012/pt-y)
Data do not include overnight or day trips. US, United States. 
*Includes patients discharged to outpatient housing.
*Jacobs D. Novacor out-of-hospital experience. Personal communi-
cation, December 1998.
†Krauskopf T. Summary of patients in release program: vented elec-
tric LVAS. Personal communications, December 1998.
‡Marchesani G. TLC-II portable driver outpatient experience.
Personal communications, December 1998.
becoming a necessity in the ever increasingly cost-con-
scious health care system.20,22 Outpatient mechanical
support may be one option in deferring hospital costs.
Although the initial cost of mechanical circulatory sup-
port is expensive, the ability to streamline patients to
discharge and maintain them on an out-of-hospital
basis may lessen the economic burden this type of ill-
ness places on society.
An outpatient LVAD program ameliorates two main
economic burdens of inpatient LVADs: one is the cost
of in-hospital care and the other is the use of hospital
resources, especially personnel. The latter is important
because our program, especially when just beginning,
had a maximum number of LVAD inpatients that could
be cared for adequately because of a finite quantity of
resources and of LVAD-trained personnel. The wait for
donor hearts is 148 days in our overall experience, and
when LVAD patients were not routinely discharged, a
difficult to manage patient load would accumulate.
Discharging LVAD patients when appropriate has
allowed us to focus on new and critically ill LVAD
patients and has allowed patients undergoing long-term
LVAD support to enter into an independent phase of
rehabilitation.
The second, more concrete economic benefit is
reduction of overall cost for taking care of an LVAD
patient after implantation. Our estimated average cost
to bridge a patient to transplantation or explantation
once discharged, including the cost of readmissions, is
$13,200. The cost of caring for an LVAD inpatient over
the same length of time, charging only for room and
board on the nonacute floor (thus excluding medicine,
medical care, and professional fees), is $165,200. Also,
to care for a healthy LVAD outpatient, which is how
our cohort spent 96% of their outpatient support time,
for 1 month ($750) is less expensive than the 1-day
charge for room and board on our nonacute hospital
service, $1600.
The other major benefit to an outpatient program is
the improvement in the quality of life when patients are
discharged home. The hospital serves as a haven for
sick people to be dependent on others for their care and
rehabilitation. However, once rehabilitation has
reached a certain level, the confines of the hospital may
inhibit the independent rehabilitation a person needs to
achieve a personal perception of mental, social, and
physical health. Patients with pneumatic LVADs,
which are not FDA approved for outpatient care, are
often supported in the hospital for extended periods of
time while awaiting donor hearts and frequently feel
stifled and “imprisoned” by the hospital.18,24,25
However, the patients with an electrical LVAD are able
to be discharged and have taken full advantage of this
opportunity. All 44 LVAD outpatients performed activ-
ities of daily living independently. They also engaged
in a host of activities, which included going to restau-
rants, the movies, and parties with friends, as well as
caring for children, ice skating, bicycle riding, playing
sports, playing in a band, and volunteer work. The high
prevalence of the three activities listed in Table VI and
the breadth of the activities listed above compel one to
believe that outpatient care allowed these patients to
fully complete their social, mental, and physical reha-
bilitation.
The above observations are based on the perceptions
and opinions of the caregivers. Recently, a thorough
and formal quality-of-life study on LVAD outpatients
was completed by Dew and associates.26 Using the
Sickness Impact Profile subclasses for physical func-
tion and for social interaction, as well as the self-report
Symptom Checklist-90 (SCL-90), LVAD outpatients
were demonstrated to improve in the physical, psycho-
logic, emotional, and social aspects of their lives when
discharged home and fared significantly better than
transplant candidates at home or LVAD inpatients. In
fact, LVAD outpatients closely resembled the trans-
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Table VIII. Available literature on LVAD outpatient programs (experiences and safety)*
No. of 
Program Journal (date) discharged patients*
Columbia-Presbyterian Medical Center J Am Coll Cardiol (1997) 19
Bad Oeynhausen Heart Center Eur J Cardiothorac Surg (1997) 6
Multicenter† ASAIO (1996) 21
Pittsburgh University Ann Thorac Surg (1996) 6‡
Texas Heart Institute ASAIO (1994) 1
Bad Oeynhausen Heart Center Correspondence (1998; unpublished) 36‡
*Discharged home (does not include day or overnight trips).
†Texas Heart Institute, Columbia Presbyterian Medical Center, Cleveland Clinic Foundation, St Luke’s Medical Center.
‡Indicates some patients discharged to hospital-run housing or rehabilitation centers.
plant recipients 7 months after transplantation in phys-
ical, psychologic, and emotional well-being.3,26
Interestingly, the transplant recipients felt more of a
burden to their family than did the LVAD outpatients.
Substantial evidence now exists through patients’
actions and perceptions, caregivers’ observations, and
some formal outcome/quality-of-life research by Dew
and associates that outpatient LVAD care provides a
better quality of life than inpatient care.1,9,10,26
We believe that an outpatient LVAD program is safe
and economical while being socially, physically, and
psychologically beneficial to the patient. Our confi-
dence in outpatient LVAD care has led to an 84% dis-
charge rate and has resulted in a minimal complication
incidence. Outpatient LVAD support is a necessary part
of an LVAD program and should be sought by most car-
diac mechanical assist programs.
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Discussion
Dr Bruce Reitz (Stanford, Calif). This is an extraordinary,
groundbreaking experience. Dr Rose and Dr Oz deserve a lot
of credit for their perseverance and the excellent care that
made this possible. They were able to discharge half of these
90 patients without any deaths and bring them to transplanta-
tion. Also impressive are the activities that the patients are
able to engage in during this time, although I must say that
snow-boarding is a little bit scary.
Dr Morales. I agree. We do not usually advise such an
activity for our patients.
Dr Reitz. These impressive results also include the fact
that only 1 patient had a thromboembolic event despite the
fact that no anticoagulants were given to these patients.
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Clearly this is very cost effective, as those of us who are
involved in assist device and transplant programs can appre-
ciate. I think your experience is now being duplicated,
although in many fewer numbers, at a number of other centers.
I would like to ask you several questions and go into a lit-
tle more of the detail that was in the manuscript. First, to
understand how this outpatient group was determined, you do
list approximately 10 criteria that patients have to meet to
become an outpatient. For example, the aortic valve has to
open during a time that the LVAD is turned down to show that
the patient has some cardiac output should the device abrupt-
ly fail. Which of these criteria are the most frequent ones that
prevent the patient from becoming an outpatient?
Dr Morales. Thank you for your comments. At first I think
it was the 30-day restriction by the FDA. Several times, we
thought we could have discharged patients sooner, but we did
not because of the 30-day restriction. Also, the physiologic
criterion is one of the critical safety nets for the outpatient
program. In the 3 patients whose devices did fail, the ability
for their native heart to give them some level of perfusion
allowed them to get into the hospital, have the problem be
diagnosed, and then have the device exchanged.
Dr Reitz. You had 9 patients in a “day trip” mode. Do all
of the patients who become outpatients go on day trips first,
or to a supervised environment, before they become com-
pletely discharged to their home?
Dr Morales. Our protocol, which switched in September
1998 when the FDA approved the TCI LVADs, was that every
patient would go through five 1-day trips with their compan-
ion and then five 3-day trips. After that, they could be com-
pletely discharged. Those were the patients who were eligible
for this study.
Dr Reitz. I believe you said that the 9 patients who were
taking day trips underwent transplantation, and that prevent-
ed them from getting to the outpatient status. Is that right?
Dr Morales. Yes, sir.
Dr Reitz. Among the 3 patients with major problems, 2
patients had graft disruptions and bleeding that necessitated
reoperation. Was the graft disruption in any particular place,
and is there something that could be done to prevent that?
Dr Morales. The hole developed probably as a result of
wear. One was identified at 6 weeks and the other at almost a
year. The Dacron graft of the TCI LVAD sometimes kinks or
bends as it is going into the ascending aorta. Dr Oz believes
it can rub against the thoracic cage, which then causes the
graft to wear. Actually, in both of these patients the low
hematocrit levels were identified during routine visits to the
outpatient clinic. Further investigation, through imaging stud-
ies, showed collections of blood surrounding the grafts.
Dr Reitz. Are you saying that these were contained rup-
tures, and not symptomatic?
Dr Morales. Yes, sir.
Dr Reitz. The manuscript mentions that some of these
patients became sensitized, with high panel reactive antibod-
ies, which we know is a problem with some long-term
LVADs. In the group that was at home, how many patients
became sensitized, and what did you do to take care of that? 
Dr Morales. I do not know the exact number because I
considered this a scheduled admission. They would have had
this same problem whether they were an inpatient or outpa-
tient. What would usually occur in these patients is a 3-day
admission for intravenous immunoglobulin G therapy to
combat the positive panel reactive antibodies.
Dr Reitz. Your success with the outpatients clearly sup-
ports the rationale for the permanent trial that I believe has
started at your institution and several others. What is the sta-
tus of that particular trial? Have you had the same kind of
results so far that you presented in this report?
Dr Morales. I do not know the data of the rematch trial. I
do not believe that information has been released publically.
Dr Rose and Dr Oz could better answer this question.
Dr Walter Dembitsky (San Diego, Calif). We all have gone
through the stage of “how can we do it.” We are passing
through the stage of “how should we do it,” and now we are
all entering the phase of “how do we do it best.” In that spirit,
we are looking at the same things in San Diego and we have
been very pleased with our outpatient LVAD population. Are
you evaluating quality-of-life indicators in these patients?
Dr Morales. We published a study I believe 3 years ago,
but that was a very small cohort. Actually, the best quality-of-
life study has been done by the Pittsburgh group, which I
mentioned as a reference in the article.26 In June 1999 in the
ASAIO Journal they published a formal quality-of-life study
using different mechanisms such as the Sickness Impact
Profile and the self-report Symptom Checklist-90. They have
shown that LVAD patients at home actually have the same
quality of life as transplant patients 7 months after receiving
their allograft and believe that their quality of life is much
better than that of transplant candidates or inpatient LVAD
patients.
Dr Dembitsky. Thank you. Finally, on that rematch, 42
patients have been randomized.
Dr Michael Reardon (Houston, Tex). In our LVAD pro-
gram we are not sending people home, but right next door at
the Texas Heart Institute Dr Frasier is. Your results are extra-
ordinarily good. These people seem to be doing very well.
What with the risks of heart transplantation and immunosup-
pression, do any of your patients tell you that they do not
want the transplant operation?
Dr Morales. Yes. One patient, an ophthalmologist, really
tried to refuse his transplant because he said he was operating
better than he had for the past few years before receiving the
LVAD. It was quite a fight to get the LVAD out, but there was
no choice.
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